37 completed. 37 Phase 2, 11 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 37 | Completed 37 |
| Phase 1 | 11 | Completed 11 |
| Phase 3 | 1 | Completed 1 |
Follow Chronic Myeloproliferative Disorders: new trials by email Literature Review of Chronic Myeloproliferative Disorders trials Research Report on Chronic Myeloproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Fludarabine, Cyclophosphamide, Total body irradiation - Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 117 | 2015-12-01 | 2022-11-03 |
| Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease anti-thymocyte globulin, sargramostim, therapeutic allogeneic lymphocytes - Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 71 | 2011-01-07 | 2017-05-30 |
| Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer donor natural killer cell infusion - Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders | Phase 1 / Phase 2 | Completed | Asan Medical Center | 47 | 2009-01-01 | 2013-02-20 |
| Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant rituximab, busulfan, carmustine - Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 48 | 2008-05-01 | 2017-06-28 |
| CC-4047 in Treating Patients With Myelofibrosis CC-4047 - Chronic Myeloproliferative Disorders, Secondary Myelofibrosis | Phase 1 / Phase 2 | Completed | Mayo Clinic | 77 | 2008-05-01 | 2019-12-30 |
| Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer anti-thymocyte globulin, cyclophosphamide, etoposide - Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 2 | Completed | City of Hope Medical Center | 32 | 2007-05-01 | 2014-09-10 |
| Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer therapeutic immune globulin, busulfan, fludarabine phosphate - Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Completed | Institut Paoli-Calmettes | 82 | 2007-03-01 | 2011-05-17 |
| Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant alemtuzumab, methylprednisolone, prednisone - Breast Cancer, Chronic Myeloproliferative Disorders | Phase 2 | Completed | Fred Hutchinson Cancer Center | 53 | 2006-07-01 | 2010-05-14 |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis tanespimycin - Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 37 | 2006-05-01 | 2012-03-15 |
| Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer anti-thymocyte globulin, busulfan, fludarabine phosphate - Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 2 | Completed | Fred Hutchinson Cancer Center | 40 | 2006-03-01 | 2010-05-14 |
| Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder ascorbic acid, arsenic trioxide, dexamethasone - Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Completed | Case Comprehensive Cancer Center | 15 | 2005-10-01 | 2020-07-27 |
| Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen rabbit anti-thymocyte globulin (ATG), therapeutic allogeneic lymphocytes, busulfan - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 / Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 54 | 2005-10-01 | 2017-07-17 |
| Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer therapeutic allogeneic lymphocytes, busulfan, cyclosporine - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 / Phase 2 | Completed | OHSU Knight Cancer Institute | 147 | 2005-06-01 | 2017-09-27 |
| Campath-1H + FK506 and Methylprednisolone for GVHD alemtuzumab, methylprednisolone, tacrolimus - Breast Cancer, Chronic Myeloproliferative Disorders | Phase 2 | Completed | Case Comprehensive Cancer Center | 34 | 2005-01-01 | 2010-06-11 |
| Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer cyclophosphamide, fludarabine phosphate, mycophenolate mofetil - Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 210 | 2004-10-01 | 2015-10-06 |
| Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia cyclophosphamide, prednisone, thalidomide - Chronic Myeloproliferative Disorders, Secondary Myelofibrosis | Phase 2 | Completed | Mayo Clinic | 22 | 2004-10-01 | 2011-03-17 |
| Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation mycophenolate mofetil, tacrolimus - Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 2 | Completed | Fred Hutchinson Cancer Center | 2004-08-01 | 2010-05-13 | |
| Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer Busulfan, Cyclophosphamide - Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 142 | 2004-06-01 | 2018-08-31 |
| Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation methotrexate, sirolimus, tacrolimus - Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 2003-06-01 | 2011-07-15 | |
| Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation ravuconazole - Breast Cancer, Chronic Myeloproliferative Disorders | Phase 1 / Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 2003-06-01 | 2012-03-08 |
Showing 20 of 37. Sign in to see all of them.
Myeloproliferative Disorders (37) · Primary Myelofibrosis (35) · Leukemia (33) · Myelodysplastic Syndromes (31) · Leukemia, Lymphocytic, Chronic, B-Cell (27) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (27) · Leukemia, Myeloid, Acute (26) · Leukemia, Myeloid, Chronic-Phase (26) · Multiple Myeloma (26) · Leukemia, Myeloid, Accelerated Phase (25) · Leukemia, Myelomonocytic, Chronic (25) · Burkitt Lymphoma (24) · Lymphoma (24) · Lymphoma, B-Cell, Marginal Zone (24) · Lymphoma, Follicular (24)
Bone Marrow Diseases (37) · Hematologic Diseases (37) · Hemic and Lymphatic Diseases (37) · Neoplasms (36) · Chronic Disease (34) · Disease Attributes (34) · Hemorrhagic Disorders (34) · Neoplasms by Histologic Type (34) · Pathologic Processes (34) · Pathological Conditions, Signs and Symptoms (34) · Leukemia, Myeloid (33) · Immune System Diseases (31) · Immunoproliferative Disorders (29) · Blood Protein Disorders (28) · Cardiovascular Diseases (28)
Cyclophosphamide (16) · Busulfan (15) · fludarabine phosphate (13) · Peripheral Blood Stem Cell Transplantation (12) · Tacrolimus (11) · Methotrexate (9) · Antilymphocyte Serum (8) · Etoposide (5) · Mycophenolic Acid (5) · Whole-Body Irradiation (5) · Cyclosporine (4) · Radiotherapy (4) · Cytarabine (3) · Melphalan (3) · Methylprednisolone (3)
Fred Hutchinson Cancer Center (11) · Case Comprehensive Cancer Center (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Cancer Treatment Centers of America (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Mayo Clinic (2) · National Institutes of Health Clinical Center (CC) (2) · Roswell Park Cancer Institute (2) · UNC Lineberger Comprehensive Cancer Center (2) · Asan Medical Center (1) · Barbara Ann Karmanos Cancer Institute (1) · City of Hope Medical Center (1) · Drexel University College of Medicine (1) · Hoag Memorial Hospital Presbyterian (1) · Institut Paoli-Calmettes (1)
United States (34) · France (2) · South Korea (1) · United Kingdom (1)
H. Joachim Deeg, MD (2) · Philip L. McCarthy, MD (2) · Ruben A. Mesa, MD (2) · Teresa Field, MD, PhD (2) · Thomas C. Shea, MD (2) · Amy E DeZern, MD (1) · Anastasios Raptis, MD (1) · Ann E. Woolfrey, MD (1) · Antonio T. Fojo, MD, PhD (1) · Ayalew Tefferi, MD (1) · Claudio Anasetti, MD (1) · David Hockenbery, MD (1) · Didier Blaise, MD (1) · Emmanuel C. Besa, MD (1) · Ephraim J. Fuchs, MD (1)
PMID 11468154, PMID 20124511, PMID 26210442, PMID 9326205
P01CA015396 (3), P30CA006973 (2), P30CA015083 (2), P30CA016086 (2), P30CA043703 (2), P30CA016058 (1), P30CA022453 (1), P30CA033572 (1)